Predictive value of MRI features on glioblastoma.
作者信息
Ma Xiaodong, Liu Jiayu
机构信息
Department of Neurosurgery, General Hospital of Chinese PLA, 28th Fuxing Road, 100853, Beijing, China.
出版信息
Eur Radiol. 2023 Jun;33(6):4472-4474. doi: 10.1007/s00330-023-09535-x. Epub 2023 Apr 5.
Abstract
摘要
相似文献
1
Predictive value of MRI features on glioblastoma.胶质母细胞瘤MRI特征的预测价值
Eur Radiol. 2023 Jun;33(6):4472-4474. doi: 10.1007/s00330-023-09535-x. Epub 2023 Apr 5.
2
Radiographic patterns of relapse in glioblastoma.复发性脑胶质瘤的影像学表现。
J Neurooncol. 2011 Jan;101(2):319-23. doi: 10.1007/s11060-010-0251-4. Epub 2010 Jun 10.
3
Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.弥散磁共振成像表型预测大肿瘤负荷复发性胶质母细胞瘤中贝伐珠单抗或手术的总生存获益。
Neurosurgery. 2020 Oct 15;87(5):931-938. doi: 10.1093/neuros/nyaa135.
4
ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma.采用表观扩散系数（ADC）定量分析对复发性胶质母细胞瘤患者是否适合接受贝伐单抗治疗进行分类。
Acta Radiol. 2020 Mar;61(3):404-413. doi: 10.1177/0284185119864842. Epub 2019 Jul 29.
5
The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).早期磁共振成像在预测贝伐珠单抗治疗复发性胶质母细胞瘤患者生存中的作用：来自前瞻性临床试验（CABARET）的结果。
Cancer. 2017 Sep 15;123(18):3576-3582. doi: 10.1002/cncr.30838. Epub 2017 Jul 5.
6
The Safety of Bevacizumab Administered Shortly after Laser Interstitial Thermal Therapy in Glioblastoma: A Case Series.激光间质热疗后短期内给予贝伐单抗治疗胶质母细胞瘤的安全性：病例系列
World Neurosurg. 2018 Sep;117:e588-e594. doi: 10.1016/j.wneu.2018.06.092. Epub 2018 Jun 19.
7
Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.复发性脑胶质瘤抗血管生成治疗早期反应的识别：酰胺质子转移加权和灌注加权 MRI 与弥散加权 MRI 的比较。
Radiology. 2020 May;295(2):397-406. doi: 10.1148/radiol.2020191376. Epub 2020 Mar 10.
8
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.贝伐单抗联合放疗/替莫唑胺治疗新诊断胶质母细胞瘤的III期试验中假性进展率和肿瘤进展模式的评估
Neuro Oncol. 2016 Oct;18(10):1434-41. doi: 10.1093/neuonc/now091. Epub 2016 Aug 11.
9
Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.高级影像学技术在鉴别胶质母细胞瘤免疫治疗后假性进展和肿瘤复发中的应用。
Front Immunol. 2021 Nov 25;12:790674. doi: 10.3389/fimmu.2021.790674. eCollection 2021.
10
Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.基于氟乙基酪氨酸 PET 和 MRI 的体素分析在抗血管生成治疗期间评估复发性脑胶质瘤。
AJR Am J Roentgenol. 2018 Dec;211(6):1342-1347. doi: 10.2214/AJR.18.19988. Epub 2018 Oct 17.
引用本文的文献
1
MRI-defined patterns of infiltration and outcome in patients with glioblastoma.胶质母细胞瘤患者的MRI定义的浸润模式与预后
Neurooncol Adv. 2025 Jul 11;7(1):vdaf114. doi: 10.1093/noajnl/vdaf114. eCollection 2025 Jan-Dec.
本文引用的文献
1
Vessel size and perfusion-derived vascular habitat refines prediction of treatment failure to bevacizumab in recurrent glioblastomas: validation in a prospective cohort.血管大小和灌注衍生的血管微环境改善了复发性胶质母细胞瘤中贝伐单抗治疗失败的预测：在前瞻性队列中的验证
Eur Radiol. 2023 Jun;33(6):4475-4485. doi: 10.1007/s00330-022-09164-w. Epub 2022 Oct 15.
2
Glioblastoma - treatment and obstacles.胶质母细胞瘤——治疗与障碍
Rep Pract Oncol Radiother. 2022 Sep 19;27(4):744-753. doi: 10.5603/RPOR.a2022.0076. eCollection 2022.
3
Synthetic MRI improves radiomics-based glioblastoma survival prediction.基于合成 MRI 的影像组学能改善胶质母细胞瘤患者的生存预测。
NMR Biomed. 2022 Sep;35(9):e4754. doi: 10.1002/nbm.4754. Epub 2022 May 21.
4
Surgical treatment of diffuse and multi-lobes involved glioma with the assistance of a multimodal technique.多模态技术辅助下的弥漫性多叶脑胶质瘤的外科治疗。
Sci Rep. 2022 Feb 28;12(1):3343. doi: 10.1038/s41598-022-07287-0.
5
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.单药或联合贝伐单抗治疗复发性胶质母细胞瘤患者的马立佐米：I/II期临床试验数据。
Neurooncol Adv. 2021 Oct 2;3(1):vdab142. doi: 10.1093/noajnl/vdab142. eCollection 2021 Jan-Dec.
6
MRI-based machine learning for determining quantitative and qualitative characteristics affecting the survival of glioblastoma multiforme.基于 MRI 的机器学习用于确定影响多形性胶质母细胞瘤生存的定量和定性特征。
Magn Reson Imaging. 2022 Jan;85:222-227. doi: 10.1016/j.mri.2021.10.023. Epub 2021 Oct 20.
7
Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment.替莫唑胺和贝伐单抗治疗后胶质母细胞瘤新生血管模式的改变及其与 DCE-MRI 衍生参数的相关性。
Sci Rep. 2017 Oct 24;7(1):13894. doi: 10.1038/s41598-017-14341-9.
8
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.贝伐珠单抗联合放疗-替莫唑胺治疗新诊断的胶质母细胞瘤。
N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345.
9
MRI manifestions correlate with survival of glioblastoma multiforme patients.磁共振成像表现与多形性胶质母细胞瘤患者的生存相关。
Cancer Biol Med. 2012 Jun;9(2):120-3. doi: 10.3969/j.issn.2095-3941.2012.02.007.
10
Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.重新评估肿瘤进展的影像学定义：灌注 MRI 定量评估复发性脑胶质瘤肿瘤部分、假性进展和放射性坏死，以预测患者的生存情况。
Neuro Oncol. 2012 Jul;14(7):919-30. doi: 10.1093/neuonc/nos112. Epub 2012 May 3.
Zotero 插件